HRP20150026T1 - 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti - Google Patents

8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti Download PDF

Info

Publication number
HRP20150026T1
HRP20150026T1 HRP20150026AT HRP20150026T HRP20150026T1 HR P20150026 T1 HRP20150026 T1 HR P20150026T1 HR P20150026A T HRP20150026A T HR P20150026AT HR P20150026 T HRP20150026 T HR P20150026T HR P20150026 T1 HRP20150026 T1 HR P20150026T1
Authority
HR
Croatia
Prior art keywords
compound
compound according
crystalline form
treatment
hydroxymethyl
Prior art date
Application number
HRP20150026AT
Other languages
English (en)
Croatian (hr)
Inventor
Holly Esken
Beth Adams Norton
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HRP20150026T1 publication Critical patent/HRP20150026T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20150026AT 2008-12-08 2009-12-07 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti HRP20150026T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds
EP09832421.3A EP2370440B1 (en) 2008-12-08 2009-12-07 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases

Publications (1)

Publication Number Publication Date
HRP20150026T1 true HRP20150026T1 (hr) 2015-02-13

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150026AT HRP20150026T1 (hr) 2008-12-08 2009-12-07 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti

Country Status (22)

Country Link
US (3) US9163024B2 (enExample)
EP (1) EP2370440B1 (enExample)
JP (1) JP5666464B2 (enExample)
KR (1) KR101743783B1 (enExample)
CN (1) CN102245606B (enExample)
AU (1) AU2009324811B2 (enExample)
BR (1) BRPI0922134A2 (enExample)
CA (1) CA2746316C (enExample)
CY (1) CY1116032T1 (enExample)
DK (1) DK2370440T3 (enExample)
EA (1) EA020037B1 (enExample)
ES (1) ES2527354T3 (enExample)
HR (1) HRP20150026T1 (enExample)
IL (1) IL213032A (enExample)
MX (1) MX2011006022A (enExample)
PL (1) PL2370440T3 (enExample)
PT (1) PT2370440E (enExample)
RS (1) RS53777B1 (enExample)
SI (1) SI2370440T1 (enExample)
SM (1) SMT201500012B (enExample)
WO (1) WO2010068581A1 (enExample)
ZA (1) ZA201103397B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863888B (zh) * 2004-02-14 2012-07-18 葛兰素史密斯克莱有限责任公司 具有hm74a受体活性的药物
HRP20100725T1 (hr) 2005-08-10 2011-01-31 Glaxosmithkline Llc Derivati ksantina kao selektivni agonisti hm74a
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
AU2024229006A1 (en) 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
JP2003534238A (ja) * 1999-12-15 2003-11-18 スミスクライン・ビーチャム・コーポレイション シス−４−シアノ−４−［３−（シクロペンチルオキシ）−４−メトキシフェニル］シクロヘキサン−１−カルボン酸の塩。
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
CN101863888B (zh) * 2004-02-14 2012-07-18 葛兰素史密斯克莱有限责任公司 具有hm74a受体活性的药物
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
HRP20100725T1 (hr) 2005-08-10 2011-01-31 Glaxosmithkline Llc Derivati ksantina kao selektivni agonisti hm74a
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
EP2370440B1 (en) 2014-11-12
AU2009324811A1 (en) 2011-06-23
AU2009324811B2 (en) 2013-01-24
US20170027945A1 (en) 2017-02-02
SMT201500012B (it) 2015-05-03
JP5666464B2 (ja) 2015-02-12
BRPI0922134A2 (pt) 2015-08-18
WO2010068581A1 (en) 2010-06-17
CA2746316C (en) 2017-01-03
US20150366870A1 (en) 2015-12-24
SI2370440T1 (sl) 2015-02-27
MX2011006022A (es) 2011-06-28
PT2370440E (pt) 2015-01-14
KR20110097816A (ko) 2011-08-31
ES2527354T3 (es) 2015-01-22
IL213032A (en) 2015-02-26
EA020037B1 (ru) 2014-08-29
CA2746316A1 (en) 2010-06-17
CY1116032T1 (el) 2017-01-25
RS53777B1 (sr) 2015-06-30
EP2370440A1 (en) 2011-10-05
CN102245606A (zh) 2011-11-16
IL213032A0 (en) 2011-07-31
US9163024B2 (en) 2015-10-20
JP2012511028A (ja) 2012-05-17
KR101743783B1 (ko) 2017-06-05
EA201170783A1 (ru) 2011-12-30
DK2370440T3 (en) 2014-12-08
EP2370440A4 (en) 2012-05-30
PL2370440T3 (pl) 2015-05-29
CN102245606B (zh) 2014-08-20
ZA201103397B (en) 2012-01-25
US20110251218A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
CZ30899A3 (cs) Substituovaný pyridin a bifenyl jako antihypercholesterinemické, antihyperlipoproteinemické a antihyperglykemické přípravky
HRP20150026T1 (hr) 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN109996797B (zh) 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法
JP2016512534A5 (enExample)
EP2041072B1 (en) Cxcr2 antagonists
BRPI0706780A2 (pt) compostos e composições como moduladores de ppar
JP2017521457A5 (enExample)
EP1636205A1 (en) Pyridinyl carbamates as hormone-sensitive lipase inhibitors
KR20110055735A (ko) 박테리아 감염 치료에 적용하기 위한 유기 화합물
NO20056056L (no) N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer
JP2011528362A5 (enExample)
WO2009056070A1 (en) Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application
WO2014025942A1 (en) Nmda receptor modulators and uses related thereto
JP4738812B2 (ja) 二官能性フェニルイソ（チオ）シアナート、それらを製造するための方法および中間体
JP2008500354A (ja) Ｐｐａｒモジュレーターとしての化合物および組成物
WO2011151436A2 (en) Novel compounds, method for use them and pharmaceutical composition containing them
JP2012511028A5 (enExample)
JP2007537289A (ja) Ｐｐａｒモジュレーターとしての化合物および組成物
KR20250086780A (ko) Cx3cr1 조절제로서의 2,4,6-삼중치환된 1,3,5-트리아진
AU2006311524A1 (en) Compounds and compositions as PPAR modulators
TWI888947B (zh) 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物
JP2020503332A5 (enExample)
JP2009514964A (ja) Ｐｐａｒモジュレーターとしての化合物および組成物
Kang et al. Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs